Carbamo(dithioperoxo)thioate Compounds for Cancer Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment for cancer cachexia, a progressive wasting syndrome caused by cancer, and existing treatments have limited clinical effectiveness.
Innovation Solution
Development of novel carbamo(dithioperoxo)thioate compounds with a nitrogen-containing aliphatic heterocyclic ring, which are designed to affect various signaling pathways to alleviate skeletal muscle atrophy and fat degradation in cancer cachexia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nutritional support and appetite stimulation therapies are used to treat cancer cachexia, then patient weight and food intake may be improved, but therapeutic effectiveness remains limited and no drug has been approved for specific cancer cachexia treatment
Solution Approach 1:
The patent changes the chemical parameters by synthesizing novel carbamo(dithioperoxo)thioate compounds with specific molecular structures (formula I) containing nitrogen-containing aliphatic heterocyclic rings, creating new pharmacological entities that may overcome the limitations of existing therapies
Solution Approach 2:
The invention creates composite molecular structures combining carbamo(dithioperoxo)thioate core with nitrogen-containing aliphatic heterocyclic rings, forming new compound classes that integrate multiple functional groups for enhanced biological activity
2Object-affected harmful factors
If anti-inflammatory cytokine antibodies are used to inhibit inflammatory factors, then inflammation may be suppressed, but cachexia development cannot be halted
Solution Approach 1:
The patent introduces novel carbamo(dithioperoxo)thioate compounds as intermediary substances that may mediate between inflammatory factor inhibition and cachexia prevention, potentially acting through multiple signaling pathways rather than single-target inhibition
3Quantity of substance
If ghrelin receptor agonists and selective androgen receptor agonists are used to stimulate appetite and muscle growth, then clinical effects are improved, but phase III clinical trials remain unsatisfactory
Solution Approach 1:
The patent segments the therapeutic approach by creating a series of related compounds (formula I with varying R1-R6 groups) that can be systematically evaluated for different biological activities, allowing identification of optimal structures for specific therapeutic effects
Solution Approach 2:
The invention moves to another dimension of molecular structure by incorporating nitrogen-containing aliphatic heterocyclic rings into the carbamo(dithioperoxo)thioate framework, creating new pharmacological properties not present in previous drug classes
Data Source
AI summary
An amino dithioperacid thioester compound, a preparation method therefor, and use thereof. The structural formula of compound is as shown in formula I: wherein m=1-11, X is a nitrogen-containing aliphatic heterocyclic ring, and a nitrogen atom in the aliphatic heterocyclic ring is connected to a carbon atom of a thiocarbonyl group. The compounds disclosed by the invention are found to be capable of relieving muscular atrophy and lipolysis caused by cancer cachexia through in-vivo and in-vitro experiments. The compounds are also capable of obviously relieving weight and food intake reduction caused by cancer cachexia in animal experiments, so that the carbamo(dithioperoxo)thioates compounds have the effect on resisting cancer cachexia, can be applied to the treatment of cancer cachexia and related diseases, and become one kind of ideal cancer cachexia treatment medicament.